{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': '2945 Townsgate Road',
 'address2': 'Suite 110',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 40,
 'askSize': 800,
 'averageDailyVolume10Day': 47936,
 'averageVolume': 79142,
 'averageVolume10days': 47936,
 'beta': None,
 'beta3Year': None,
 'bid': 26,
 'bidSize': 900,
 'bookValue': -13.379,
 'category': None,
 'circulatingSupply': None,
 'city': 'Westlake Village',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 27.825,
 'dayLow': 26.88,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -12.201,
 'enterpriseToRevenue': None,
 'enterpriseValue': 789920640,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 30.097,
 'fiftyTwoWeekHigh': 40.88,
 'fiftyTwoWeekLow': 17.1,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 16503641,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 43,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.06846,
 'heldPercentInstitutions': 0.67096,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/arcutis.com',
 'longBusinessSummary': 'Arcutis Biotherapeutics, Inc., a biopharmaceutical '
                        'company, focuses on developing and commercializing '
                        'treatments for dermatological diseases. Its lead '
                        'product candidate is ARQ-151, a topical cream '
                        'formulation of roflumilast that is in Phase III '
                        'clinical trials for the treatment of plaque psoriasis '
                        'and atopic dermatitis. The company is also developing '
                        'ARQ-154, a topical foam formulation of ARQ-151 for '
                        'the treatment of seborrheic dermatitis and scalp '
                        'psoriasis; ARQ-252, a selective topical small '
                        'molecule inhibitor of janus kinase type 1 for hand '
                        'eczema and other inflammatory dermatoses; and '
                        'ARQ-255, a topical formulation of ARQ-252 designed to '
                        'reach deeper into the skin to the postulated site of '
                        'inflammation in alopecia areata. The company was '
                        'formerly known as Arcutis, Inc. and changed its name '
                        'to Arcutis Biotherapeutics, Inc. in October 2019. '
                        'Arcutis Biotherapeutics, Inc. was founded in 2016 and '
                        'is headquartered in Westlake Village, California.',
 'longName': 'Arcutis Biotherapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 1040857536,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_549019944',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -63351000,
 'nextFiscalYearEnd': 1640908800,
 'open': 27.31,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.33,
 'phone': '805 418 5006',
 'previousClose': 27.6,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 27.825,
 'regularMarketDayLow': 26.88,
 'regularMarketOpen': 27.31,
 'regularMarketPreviousClose': 27.6,
 'regularMarketPrice': 27.31,
 'regularMarketVolume': 39919,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 38154600,
 'sharesPercentSharesOut': 0.0436,
 'sharesShort': 1662214,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1281019,
 'shortName': 'Arcutis Biotherapeutics, Inc.',
 'shortPercentOfFloat': 0.0925,
 'shortRatio': 14.05,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ARQT',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -10.269,
 'twoHundredDayAverage': 28.3212,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '2fecbc50-3c9a-3138-8f51-5317e20e84cd',
 'volume': 39919,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.arcutis.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '91361'}